Virtu KCG Holdings LLC acquired a new position in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 62,287 shares of the biopharmaceutical company’s stock, valued at approximately $728,000. Virtu KCG Holdings LLC owned approximately 0.19% of Bellicum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Principal Financial Group Inc. increased its holdings in Bellicum Pharmaceuticals by 0.7% during the 1st quarter. Principal Financial Group Inc. now owns 83,338 shares of the biopharmaceutical company’s stock worth $1,029,000 after purchasing an additional 610 shares in the last quarter. American International Group Inc. increased its holdings in Bellicum Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 12,902 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 852 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Bellicum Pharmaceuticals by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 95,934 shares of the biopharmaceutical company’s stock worth $1,184,000 after purchasing an additional 935 shares in the last quarter. Teachers Advisors LLC increased its holdings in Bellicum Pharmaceuticals by 5.5% during the 4th quarter. Teachers Advisors LLC now owns 35,608 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 1,844 shares in the last quarter. Finally, ProShare Advisors LLC increased its holdings in Bellicum Pharmaceuticals by 14.9% during the 2nd quarter. ProShare Advisors LLC now owns 19,393 shares of the biopharmaceutical company’s stock worth $227,000 after purchasing an additional 2,513 shares in the last quarter. 55.73% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/10/06/virtu-kcg-holdings-llc-buys-new-stake-in-bellicum-pharmaceuticals-inc-blcm.html.

In related news, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction that occurred on Thursday, July 13th. The shares were sold at an average price of $12.26, for a total transaction of $169,469.98. Following the completion of the sale, the vice president now owns 14,314 shares of the company’s stock, valued at $175,489.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, July 10th. The shares were sold at an average price of $11.54, for a total transaction of $115,400.00. The disclosure for this sale can be found here. Insiders have sold 24,260 shares of company stock valued at $290,048 in the last three months. 18.77% of the stock is owned by insiders.

Bellicum Pharmaceuticals, Inc. (NASDAQ BLCM) opened at 11.44 on Friday. The stock’s market cap is $380.11 million. The stock has a 50 day moving average price of $10.41 and a 200-day moving average price of $11.58. Bellicum Pharmaceuticals, Inc. has a 52 week low of $7.41 and a 52 week high of $23.11.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative net margin of 17,957.31% and a negative return on equity of 70.74%. During the same quarter in the prior year, the company posted ($0.61) EPS. On average, equities analysts anticipate that Bellicum Pharmaceuticals, Inc. will post ($3.02) EPS for the current fiscal year.

BLCM has been the subject of a number of recent research reports. Jefferies Group LLC reissued a “buy” rating and set a $16.00 price objective (down from $18.00) on shares of Bellicum Pharmaceuticals in a report on Thursday, August 10th. Raymond James Financial, Inc. set a $18.00 price objective on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 9th. Cantor Fitzgerald set a $32.00 price objective on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Ladenburg Thalmann Financial Services set a $31.00 price objective on Bellicum Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, June 24th. Finally, Wells Fargo & Company restated an “outperform” rating and issued a $31.00 target price on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. Bellicum Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $26.20.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Want to see what other hedge funds are holding BLCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM).

Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.